Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 24,178 | 31,606 | 39,648 | 36,600 | 31,598 |
| TOTAL | $25,785 | $33,507 | $41,820 | $37,998 | $33,334 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 101 | 108 | 7 | 40 | 71 |
| TOTAL | $101 | $108 | $7 | $40 | $71 |
| Total Assets | $25,886 | $33,615 | $41,827 | $38,038 | $33,405 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,964 | 1,906 | 1,805 | 1,917 | 924 |
| Accrued Expenses | 7,864 | 7,629 | 7,163 | 6,382 | 5,065 |
| TOTAL | $10,892 | $9,535 | $9,033 | $8,299 | $6,054 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 30,217 | 30,273 | 30,178 | 20,490 | 10,235 |
| TOTAL | $30,217 | $30,273 | $30,178 | $20,490 | $10,235 |
| Total Liabilities | $41,109 | $39,808 | $39,211 | $28,789 | $16,289 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 59,396 | 59,389 | 59,358 | 59,341 | 59,275 |
| Common Shares | 59 | 59 | 59 | 59 | 59 |
| Retained earnings | -290,287 | -280,610 | -270,694 | -263,407 | -254,850 |
| Other shareholders' equity | 2,233 | 2,250 | 2,250 | 2,250 | 2,250 |
| TOTAL | $-15,223 | $-6,193 | $2,616 | $9,249 | $17,116 |
| Total Liabilities And Equity | $25,886 | $33,615 | $41,827 | $38,038 | $33,405 |